Rheumatologist Dr Thomas Batty and haematologist Dr Emma Conway O'Brien describe a rational approach to investigating multifocal pain ...
inews.co.uk on MSN
We were told we had cancer on same day. My mum died but I survived
A mum and her daughter were both told they had cancer on the same day – within just hours of […] ...
According to MarketsandMarkets™, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%.
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...
DelveInsight's BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
His passing came after a five-year battle with multiple myeloma, a cancer that begins in the plasma cells in the bone marrow, ...
The FDA issued draft guidance Jan. 21 proposing the use of minimal residual disease and complete response as primary endpoints to support accelerated approval of drugs for multiple myeloma. The draft ...
Explore the transformative potential of bispecific antibodies in multiple myeloma, offering hope for improved patient outcomes and possible cures. In this episode, experts discuss how bispecific ...
OSF recently confirmed that their patients personal and medical information may have been exposed in a breach involving its former electronic health record software vendor, Cerner. According to a ...
Andrew Yee, MD, introduces the discussion by reviewing treatment challenges, patient education, and decision-making in relapsed/refractory multiple myeloma. The final portion of the discussion focuses ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results